1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Welcure Drugs and Pharmaceuticals Ltd.

Welcure Drugs and Pharmaceuticals Ltd.

BBSE:WELCURE
0.20
INR
+0.01
(+5.26%)
-0.18EPS
296.63MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
0.03
0.04
0.08
0.01
- -
0.07
0.07
0.11
0.09
- -
- -
0.2
2.96
3.82
Basic EPS, GAAP
- -
- -
0.07
- -
- -
- -
-0.01
0.05
0.02
0.01
-0.01
0.02
-0.04
-0.18
Free Cash Flow per Basic Share
- -
0.01
-0.04
- -
- -
- -
-0.01
0.03
0.02
0.01
-0.01
-1.79
0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.06
-0.05
0.01
0.03
0.01
0.02
0.01
0.05
0.07
1.12
0.99
9.11
0.78
0.78
Tangible Book Value per Share
-0.06
-0.05
0.01
0.03
0.01
0.02
0.01
0.05
0.07
1.12
0.99
9.11
0.78
0.78
Basic Weighted Avg Shares
12
12
12
133
133
12
12
12
12
148
149
1,238
1,236
956
Sales/Revenue/Turnover
- -
1
1
1
1
1
1
1
1
- -
- -
246
3,655
3,655
Operating Margin (%)
4.53
6.9
82.21
30.8
-41
2.91
-11.88
41.26
22.52
- -
- -
3.54
-1.9
-2.02
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
1
- -
- -
- -
- -
1
- -
1
-2
22
-55
-170
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
21.94
- -
- -
Profit Margin (%)
7.81
11.58
85.59
30.8
-38.8
4.88
-11.39
41.36
22.46
- -
- -
8.84
-1.5
-4.65
Working Capital
-1
-1
- -
- -
- -
- -
- -
- -
1
- -
- -
1,409
-556
-556
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1,232
- -
- -
Total Equity
-1
-1
- -
- -
- -
- -
- -
1
1
15
13
1,025
970
970
Return on Invested Capital (%)
- -
- -
-263.49
108.66
- -
10.63
- -
130.47
29.11
5.11
- -
0.6
- -
- -
Return on Capital (%)
-3.62
-7.64
-274.33
108.66
- -
17.83
- -
131.74
29.03
12.65
- -
1.91
- -
- -
Return on Common Equity (%)
- -
- -
- -
108.66
-65.76
17.83
-49.46
131.74
29.03
12.65
-12.24
4.18
-5.5
-17.03

Capital Structure

INR

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
1,232
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,236
1,236
1,236
Market Capitalization
618
519
297

Working Capital

INR

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
5,480
- -
3,575
Cash, Cash Equivalents & STI
1
- -
6
Accounts Receivable, Net
3,845
- -
2,134
Inventories
1,435
- -
1,435
Total Current Liabilities
3,754
- -
4,132
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
964.75%
1,818.71%
-5.36%
Free Cash Flow
17,253.27%
34,803.42%
-100.78%
Net Income, GAAP
-307.93%
-338.46%
-352.99%
Sales/Revenue/Turnover
- -
- -
1,388.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
246
88
212
246
2026
2,999
656
- -
- -
3,655

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.01
-0.02
- -
-0.01
2025
-0.02
0.23
- -
0.02
0.02
2026
2.07
0.07
0.01
-0.4
-0.04

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chintan Didawala Ganpat
Full Time Employees
- -
Sector
Health technology
Industry
Pharmaceuticals: major
Address
608, Shree Balaji Hights New Delhi DE India 380051
IPO Date
Nov 27, 2000
Website
welcuredrugs.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Welcure Drugs & Pharmaceuticals Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company offers a diverse portfolio of products including tablets, capsules, syrups, injectables, ointments, and powders. Its product offerings cover various therapeutic categories such as antibiotics, analgesics, anti-inflammatory drugs, anti-diabetic drugs, cardiovascular drugs, gastrointestinal drugs, and dermatological products. Welcure Drugs serves both domestic and international markets with a focus on innovation and quality. Founded in 1962, Welcure Drugs is headquartered in Mumbai, Maharashtra, India. The company operates through multiple production facilities and maintains a broad distribution network across India and abroad. It targets healthcare providers, hospitals, clinics, and retail pharmacies as its primary customer base. In recent developments within the last 1-2 years, Welcure Drugs & Pharmaceuticals Limited has pursued strategic expansion through new product launches and increased focus on export markets. The company also continues to strengthen partnerships and collaborations to enhance its research and development capabilities. There have been no major name changes or reorganizations reported recently. The company remains committed to broadening its therapeutic product lines and geographic reach in Asia and other emerging markets. Overall, Welcure Drugs & Pharmaceuticals Limited is recognized for its comprehensive range of pharmaceutical products, sustained operational growth, and ongoing initiatives that align with its strategy to strengthen its presence in the competitive pharmaceutical industry.